(Total Views: 473)
Posted On: 03/09/2017 11:56:00 PM
Post# of 22801
$HRTX,
The Heron Therapeutics Inc (HRTX) Earns Buy Rating from Analysts at Needham & Company LLC
March 10, 2017 Darlene McCollum
The Heron Therapeutics Inc (HRTX) Earns Buy Rating from Analysts at Needham & Company LLC
Needham & Company LLC started coverage on shares of Heron Therapeutics Inc (NASDAQ:HRTX) in a research note published on Monday. The brokerage issued a buy rating and a $28.00 price target on the biotechnology company’s stock.
A number of other brokerages also recently issued reports on HRTX. JMP Securities reaffirmed a buy rating on shares of Heron Therapeutics in a research report on Wednesday, November 9th. Jefferies Group LLC set a $29.00 target price on shares of Heron Therapeutics and gave the stock a buy rating in a research note on Thursday, January 5th. Cantor Fitzgerald reiterated an overweight rating and issued a $34.00 target price on shares of Heron Therapeutics in a research note on Friday, January 6th. Cowen and Company reiterated a buy rating and issued a $40.00 target price on shares of Heron Therapeutics in a research note on Sunday, December 11th. Finally, Zacks Investment Research cut shares of Heron Therapeutics from a hold rating to a sell rating in a research note on Tuesday, January 10th. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $36.22.
Heron Therapeutics (NASDAQ:HRTX) traded down 1.37% during mid-day trading on Monday, hitting $14.40. 596,714 shares of the stock were exchanged. Heron Therapeutics has a 52 week low of $12.21 and a 52 week high of $25.46. The company has a 50-day moving average of $13.50 and a 200-day moving average of $15.91.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Thursday, February 23rd. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by $0.05. On average, equities analysts forecast that Heron Therapeutics will post ($3.49) EPS for the current year.
In other news, Director Kevin C. Tang bought 2,459,016 shares of the business’s stock in a transaction that occurred on Thursday, January 19th. The shares were purchased at an average cost of $12.20 per share, for a total transaction of $29,999,995.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 20.31% of the stock is currently owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the company. FMR LLC raised its stake in Heron Therapeutics by 0.4% in the fourth quarter. FMR LLC now owns 5,872,839 shares of the biotechnology company’s stock worth $76,934,000 after buying an additional 20,545 shares during the last quarter. Janus Capital Management LLC raised its position in shares of Heron Therapeutics by 13.4% in the fourth quarter. Janus Capital Management LLC now owns 4,575,807 shares of the biotechnology company’s stock valued at $59,947,000 after buying an additional 542,007 shares in the last quarter. Broadfin Capital LLC raised its position in shares of Heron Therapeutics by 23.8% in the fourth quarter. Broadfin Capital LLC now owns 3,899,587 shares of the biotechnology company’s stock valued at $51,085,000 after buying an additional 749,587 shares in the last quarter. Baker BROS. Advisors LP bought a new position in shares of Heron Therapeutics during the third quarter valued at approximately $49,230,000. Finally, Highland Capital Management LP raised its position in shares of Heron Therapeutics by 140.2% in the fourth quarter. Highland Capital Management LP now owns 1,562,817 shares of the biotechnology company’s stock valued at $20,473,000 after buying an additional 912,086 shares in the last quarter.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
The Heron Therapeutics Inc (HRTX) Earns Buy Rating from Analysts at Needham & Company LLC
March 10, 2017 Darlene McCollum
The Heron Therapeutics Inc (HRTX) Earns Buy Rating from Analysts at Needham & Company LLC
Needham & Company LLC started coverage on shares of Heron Therapeutics Inc (NASDAQ:HRTX) in a research note published on Monday. The brokerage issued a buy rating and a $28.00 price target on the biotechnology company’s stock.
A number of other brokerages also recently issued reports on HRTX. JMP Securities reaffirmed a buy rating on shares of Heron Therapeutics in a research report on Wednesday, November 9th. Jefferies Group LLC set a $29.00 target price on shares of Heron Therapeutics and gave the stock a buy rating in a research note on Thursday, January 5th. Cantor Fitzgerald reiterated an overweight rating and issued a $34.00 target price on shares of Heron Therapeutics in a research note on Friday, January 6th. Cowen and Company reiterated a buy rating and issued a $40.00 target price on shares of Heron Therapeutics in a research note on Sunday, December 11th. Finally, Zacks Investment Research cut shares of Heron Therapeutics from a hold rating to a sell rating in a research note on Tuesday, January 10th. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $36.22.
Heron Therapeutics (NASDAQ:HRTX) traded down 1.37% during mid-day trading on Monday, hitting $14.40. 596,714 shares of the stock were exchanged. Heron Therapeutics has a 52 week low of $12.21 and a 52 week high of $25.46. The company has a 50-day moving average of $13.50 and a 200-day moving average of $15.91.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Thursday, February 23rd. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by $0.05. On average, equities analysts forecast that Heron Therapeutics will post ($3.49) EPS for the current year.
In other news, Director Kevin C. Tang bought 2,459,016 shares of the business’s stock in a transaction that occurred on Thursday, January 19th. The shares were purchased at an average cost of $12.20 per share, for a total transaction of $29,999,995.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 20.31% of the stock is currently owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the company. FMR LLC raised its stake in Heron Therapeutics by 0.4% in the fourth quarter. FMR LLC now owns 5,872,839 shares of the biotechnology company’s stock worth $76,934,000 after buying an additional 20,545 shares during the last quarter. Janus Capital Management LLC raised its position in shares of Heron Therapeutics by 13.4% in the fourth quarter. Janus Capital Management LLC now owns 4,575,807 shares of the biotechnology company’s stock valued at $59,947,000 after buying an additional 542,007 shares in the last quarter. Broadfin Capital LLC raised its position in shares of Heron Therapeutics by 23.8% in the fourth quarter. Broadfin Capital LLC now owns 3,899,587 shares of the biotechnology company’s stock valued at $51,085,000 after buying an additional 749,587 shares in the last quarter. Baker BROS. Advisors LP bought a new position in shares of Heron Therapeutics during the third quarter valued at approximately $49,230,000. Finally, Highland Capital Management LP raised its position in shares of Heron Therapeutics by 140.2% in the fourth quarter. Highland Capital Management LP now owns 1,562,817 shares of the biotechnology company’s stock valued at $20,473,000 after buying an additional 912,086 shares in the last quarter.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼
